Leading pharmaceutical manufacturers from China have shown serious interest in locating facilities in Uzbekistan. Investors from Jiangsu Province familiarized themselves with the capabilities of the specialized pharmaceutical park in Tashkent, where they were presented with government support measures, tax incentives, and programs for localizing innovative technologies. Special attention was drawn to infrastructure, logistics, and the project support system based on the "single window" principle.
More than 20 companies have expressed their readiness to develop long-term partnerships in the production of medicines, biopharmaceutical products, and medical technologies. An agreement was reached on a visit by a delegation at the beginning of next year — investors intend to study industry sites in detail and move on to discussing specific projects, including the possible location of factories in Uzbekistan.
China remains a key source of foreign investment for the country. At the end of January–September 2025, it accounted for almost 40% of all funds raised, which makes pharmaceutical initiatives a logical continuation of expanding economic cooperation.
